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Abstract 20 
Since 2015, the Swiss Federal Office of Public Health registered an increase of notifications 21 
of STEC, probably due to the adoption of culture independent stx screening tests in 22 
diagnostic laboratories. This study aimed to identify the serotypes and virulence genes of 120 23 
STEC isolated from human clinical stx positive specimens during 2017 in order to estimate 24 
any changes in serotype distribution and toxin profiles of STEC compared to the time span 25 
2010–2014. Culturing of STEC from stool samples was achieved using the streak plate 26 
technique on MacConkey agar. We performed O and H serotyping by PCR and by micro 27 
array. Virulence genes were identified and subtyped using molecular methods, including stx1 28 
and stx2 subtypes, and the intimin encoding gene, eae. STEC were recovered from 27.5% of 29 
the stx positive samples. STEC O157:H7 accounted for 7.5% of all isolates, and STEC 30 
O80:H2, O91:H10/H14/H21, O103:H2/H11, and O26:H11 accounted for 36.9% of the non-31 
O157 strains. Forty-five isolates with stx1 variants, 47 with stx2 variants and 28 isolates with 32 
both stx1 and stx2 variants were identified. Forty (33.3% of all isolates) carried the subtypes 33 
associated with high pathogenic potential, stx2a, stx2c, or stx2d. The eae gene for intimin 34 
was detected in 54 strains (45% of all strains). Compared to 2010–2014, our data show that 35 
the proportion of the so called "top five" serogroups, STEC O26, O111, O103, and O157 36 
declined from 53.7% to 28.3% in 2017. The proportion of isolates with stx2a, stx2c, or stx2d 37 
decreased from 50.5% to 33.3%. We also observed an increase of STEC harbouring the low 38 
pathogenic subtypes stx2b and stx2e from 12.6% to 29.2%, and of eae negative STEC from 39 
29.5% in 2010–2014 to 55% in 2017. Simultaneously, there was a sharp increase of the 40 
patients' median age from 24 years to 46.5 years. Clinical manifestations in the patients 41 
included abdominal pain without diarrhea (22.3%), diarrhea (77.7%), and the haemolytic-42 
uremic syndrome (HUS) (7.4%). Our data show that a greater number and a wider range of 43 
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STEC serotypes are detected by culture-independent testing, with implications for public 44 
health services. 45 
 46 
 47 
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1. Introduction 50 
Shiga toxin (Stx)-producing Escherichia coli (STEC) are etiological agents of outbreaks and 51 
of sporadic cases of human gastrointestinal illnesses which may include non-bloody or 52 
bloody diarrhea, haemorrhagic colitis (HC), and the haemolytic uremic syndrome (HUS) 53 
(Karch et al., 2005). STEC are characterized by the production of one or more Stx, which 54 
consist of two groups designated Stx1 (consisting of the three variants Stx1a, Stx1c and 55 
Stx1d) and Stx2 (composed of seven distinct variants Stx2a, Stx2b, Stx2c, Stx2d, Stx2e, 56 
Stx2f, and Stx2g). STEC associated with severe disease tend to feature variants Stx2a, Stx2c 57 
and Stx2d, whereas STEC producing Stx2b and Stx2e are linked to mild clinical symptoms or 58 
asymptomatic fecal carriage (Stephan and Hoelzle, 2000; Friedrich et al., 2002; Fuller et al., 59 
2011). Virulence may further be increased by the presence of intimin, the product of the eae 60 
gene, which mediates attaching and effacing lesions on gastrointestinal epithelial cells (Kaper 61 
et al., 2004). STEC belonging to the serogroups O157, O26, O103, O111, and O145 62 
constitute the so called “top five” serogroups of human pathogenic STEC in the EU and 63 
Switzerland, and are considered, together with a few others such as O91 and O113, important 64 
serogroups in public health (EFSA, 2017). 65 
Human infection with STEC is a notifiable disease in Switzerland. Notification of confirmed 66 
cases to the federal office for public health (FOPH) is based on the isolation of STEC from 67 
faeces, or on the detection of stx1 and/or stx2 in faeces or from a clinical isolate of E. coli. 68 
The number of notifications of STEC in Switzerland has been increasing since 2015, possibly 69 
due to the introduction of PCR based, increasingly sensitive stx screening tests in laboratory 70 
testing practices. However, such culture-independent testing (CIDT) generally does not yield 71 
an isolate, and positive results are not always culture confirmed. From the public health point 72 
of view, the advantages of rapid and broad range pathogen detection are therefore challenged 73 
by possible loss of strain subtyping with consequent disruption of monitoring trends in 74 
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serotype or Stx distribution (Cronquist et al., 2012). Recognition of the trends in serotypes 75 
and toxin profiles of STEC is however of great importance in order to estimate their potential 76 
for causing disease and to anticipate epidemiological changes. The aim of this study was to 77 
gain epidemiological and serotyping information on STEC isolated during 2017. Therefore, 78 
from May to December 2017, the FOPH requested all diagnostic laboratories to forward 79 
clinical materials that tested positive for stx by CIDT to the Swiss National Reference Centre 80 
for Enteropathogenic Bacteria and Listeria (NENT) for culture and further strain 81 
characterization. The isolates were analysed with regard to their serotypes, stx subtypes and 82 
presence of the eae gene. The results were compared with earlier data from Switzerland 83 
investigated over the 5-year period 2010-2014 (Fierz et al., 2017). 84 
 85 
2. Material and Methods 86 
2.1. Sample collection 87 
Human stool samples that tested positive for stx using multiplex molecular methods were 88 
submitted to the NENT from May to December 2017 from clinical diagnostic laboratories 89 
distributed nationwide. 90 
From a total of 457 submitted specimens, 436 were included for analysis after the elimination 91 
of repeat specimens (i.e., specimens obtained from the same patient). Of the 436 patients, 92 
data of age and gender were known for 431 individuals. Thereof, 240 (55.7%) were from 93 
female and 191 (44.3 %) were from male patients. The median age was 46.5 years (range 0–94 
99 years). Forty-six (10.7%) were isolated from patients ≤ 5 years of age.  95 
 96 
 97 
2.2. Strain isolation 98 
 6 
Specimens were cultured on MacConkey agar using the streak plate technique. From each 99 
plate, six individual colonies, if possible of different morphology, were picked und 100 
subcultured on sheep blood agar (DifcoTM Columbia Blood Agar Base EH; Becton Dickinson 101 
AG, Allschwil, Switzerland). Isolates that were confirmed to possess stx (stx1 102 
and/or stx2) by real-time PCR (LightCycler R 2.0 Instrument, Roche Diagnostics 103 
Corporation, Indianapolis, IN, USA) (EURL, 2013a) were selected for further analysis. From 104 
plates yielding more than one stx positive colony, one isolate was randomly chosen for 105 
subsequent characterization. Proportions of STEC in stool samples were defined as the 106 
numbers of stx positive colonies among six E. coli colonies.  107 
 108 
2.3. Serotyping 109 
Strains were examined by PCR for the presence of genes associated with 14 selected 110 
serogroups including the top-five serogroups, namely O26, O45, O55, O80, O91, O103, 111 
O104, O111, O113, O121, O128, O145, O146, and O157 (Perelle et al., 2004; EURL, 2013a; 112 
EURL, 2014; Soysal et al., 2016). Strains were tested for the presence of flagellar genes 113 
related to H2, H4, H7, H8, H10, H11, H19, H21, H25, and H28 (Mora et al., 2012; EURL, 114 
2013b; Beutin et al., 2015; Alonso et al., 2017). Strains belonging to other O groups and H 115 
types were serotyped using the AlereTM E. coli SeroGeno typing AS-1 kit (Alere 116 
Technologies, Jena, Germany). 117 
 118 
2.4. Virulence markers 119 
The identification of stx1 subtypes (stx1a, stx1c, stx1d) and stx2 subtypes (stx2a, stx2b, stx2c, 120 
stx2d, stx2e, stx2g) was carried out by conventional PCR amplification (Scheutz et al., 2012). 121 
Screening of the strains for eae was performed by real-time PCR according to the guidelines 122 
of the European Union Reference laboratory (EURL, 2013a). 123 
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3. Results 125 
3.1. Recovery rate 126 
Out of a total of 436 human fecal specimens that tested positive by multiplex PCR for the 127 
presence of stx, 120 samples yielded an STEC isolate for further characterisation, amounting 128 
to a recovery rate of 27.5%. 129 
Categorising the 120 samples into those with high numbers of stx positive colonies (five or 130 
six positive colonies per sample), those with intermediate numbers (three or four positive 131 
colonies) and those with low numbers (one or two colonies), resulted in 46 (38.3%) stool 132 
samples with a high proportion of STEC colonies, 35 (29.2%) with an intermediate 133 
proportion, and 39 (32.5%) stool samples with a low proportion of STEC, respectively 134 
Strains exhibiting high or low colony numbers are listed in Table 1. 135 
 136 
3.2. Serological diversity 137 
Twenty-five different O-serogroups were identified among the 120 STEC isolates, in addition 138 
to 17 O-non-typeable (Ont) serogroups, and 4 ambiguous results. Eighteen different H-types 139 
were determined, including two non-typeable H-types and two ambiguous results. An 140 
overview of the serotypes is given in Table 1.  141 
Among the 120 isolates, 9 (7.5%) were O157:H7, and 111 (92.5%) were non-O157 STEC 142 
strains. Together with STEC O157, the top five serogroups were represented by STEC O103 143 
(n=11), O145 (n=6), and O26 (n=8), amounting to 28.3% of the isolates. No STEC O111 144 
were detected. Isolates belonging to O80:H2 (n=11), and O91:H10/H14/H21 (n=11) 145 
accounted each for 9.2% of the isolates, respectively. Other serotypes included 146 
O174:H2/H8/H21 (n=7; 5.8%), and O146:H21 (n=6; 5%) (Table 1). Other serotypes were 147 
represented by four or less STEC isolates (Table 1). 148 
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 149 
3.3. Distribution of virulence genes among the serotypes 150 
Of the 120 STEC strains, 45 (37.5%) carried stx1 genes only: stx1a (n = 35), stx1c (n = 9) 151 
and stx1d (n=1). Forty-seven strains (39.1%) carried stx2 genes only: stx2a (n = 14), stx2b (n 152 
= 14), stx2c (n = 5), stx2d (n = 12), and stx2e (n = 2). Twenty-eight (23.3%) harboured 153 
combinations of stx1 and stx2 genes. Forty (33.3% of all isolates) carried the subtypes 154 
associated with high pathogenic potential, stx2a, stx2c, or stx2d (Table 1). The 155 
majority thereof (n = 25/62.5% of the 40 strains) were associated with O80:H2 (n=11), 156 
O157:H7 (n = 9) and O145:H28 (n = 5).  157 
Thirty-five (29.2%) isolates harboured the low pathogenic subtypes stx2b and stx2e and were 158 
mainly associated to the serogroup O146 and Ont serogroups. 159 
The eae gene encoding intimin was detected in 54 strains (45% of all strains). Thereof, 31 160 
(57.4% of the eae positive strains) were associated with stx2a, stx2c, or stx2d, and one (4.3%) 161 
with stx2b. The remaining 22 (40.7%) of the eae positive isolates carried stx1a alone (Table 162 
1).  163 
The majority (25 strains, 80.6%) of the eae positive strains harbouring stx2 subtypes 164 
belonged to STEC O80:H2, O145:H28, and O157:H7. By contrast, of the 66 (55% of all 165 
strains) that tested negative for eae, nine (13.6% of all eae negative strains) harboured stx2a, 166 
stx2c, or stx2d, while 34 (51.5%) were associated with stx2b or stx2e. The remaining 23 167 
(34.8%) carried stx1a stx1c or stx1d alone (Table 1). 168 
The distribution of serogroups and genotypes compared to earlier data from 2010-2014 (Fierz 169 
et al., 2017) is illustrated in Figure 1. 170 
171 
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3.4. Relationship between STEC type, age of patients, clinical symptoms, and 172 
proportions of stx positive E. coli in stool samples  173 
 174 
Patients were classified into four groups, according to their age at the time of sampling. Age 175 
group 1 consisted of infants and children ≤ 5 years of age (n=14), group 2 contained children 176 
and young adults between 6 and 17 years (n=16). Group 3 consisted of adult patients between 177 
18 and 60 years (n=56), and group 4 of patients >60 years (n=33). For one patient, the age 178 
was unknown (Table 1). Clinical data were provided for 94 (78.3%) of the patients. 179 
Abdominal pain without diarrhea (AP) was reported for 21 (22.3%) of the patients. The 180 
majority (77.7%) suffered from diarrhea (D). HUS was present in 7 (7.4%) of the patients, six 181 
thereof with D, and one with AP. Two further patients (2.1%) had presumptive HUS with 182 
acute kidney failure (AKF). Nineteen (20.2%) patients were hospitalized (two patients with 183 
AP only and 17 patients with D). 184 
The distribution of STEC serotypes and of stx2 and eae genes among the patients’ age groups 185 
is listed in Table 1. STEC belonging to the top five serogroups were found in 71.2% of the 186 
STEC infected children from age group 1 and in 56.3% from age group 2.  Infections due to 187 
the top five STEC serotypes were less frequent among age group 3 (16.1% of the patients), 188 
and age group 4 (18.2% of the patients). By contrast, of the two most prevalent serogroups 189 
from this study, STEC O80 was isolated more frequently from patients in age group 4 (15.2% 190 
of the patients) than from patients in groups 1 (7.1%), group 2 (6.3%) and group 3 (7.1%), 191 
respectively. STEC O91 was detected only among isolates from patients of age groups 3 and 192 
4, accounting for 16.1% and 6% of the infections, respectively. STEC harbouring 193 
stx2a/stx2d/stx2c were frequent among patients from age groups 1, 2 and 4 (50%, 43.8%, and 194 
42.4% respectively), and least frequent among patients from age group 3 (19.6%). STEC 195 
containing stx2b/stx2e was more frequent among patients from age groups 3 and 4 (33.9% 196 
and 33.3%, respectively), compared to patients from age groups 1 and 2 (7.1% and 25%, 197 
 10 
respectively). Similarly, eae positive STEC were observed at higher rates among patients 198 
from groups 1 and 2 (85.7% and 62.5%, respectively) than among those from groups 3 and 4 199 
(30.4% and 42.2%, respectively). By contrast, eae negative STEC were remarkably less 200 
frequent in isolates from patients of age groups 1 and 2 (14.3% and 37.5%, respectively) than 201 
in those from group 3 and 4 (69.6% and 57.6%, respectively). The distribution of STEC 202 
serogroups and of stx2 and eae genes among the patients’ age groups is illustrated in Figure 203 
2A and B, respectively. 204 
STEC serotypes and virulence genes associated with patients with abdominal pain only, 205 
diarrhea, HUS, and with patients that were hospitalised are listed in Table 1. STEC belonging 206 
to the top five serogroups were found in 14.3% of 21 patients with AP, in 30.1 % of 73 207 
patients with D and in 42.9% of 7 patients with HUS (Table 1). The top five serogroups were 208 
furthermore associated with 31.6% of 19 hospitalised patients. STEC O80 was isolated from 209 
4.8% of patients with AP and 12.3% of patients with D. Moreover, STEC O80:H2 was 210 
associated with one case of HUS, two cases of AKF and isolated from 21% of hospitalised 211 
patients (Table 1). STEC O91 was detected at similar rates among patients with AP and D 212 
(14.3% and 9.6%, respectively), in one HUS case and in 15.8% of hospitalised patients.  213 
STEC harbouring stx2a/stx2d/stx2c were less frequent among patients with AP (14.3%), than 214 
among isolates from patients with D (41%) and HUS patients (100%), and were found in 215 
68.4% of hospitalised patients. Similarly, eae positive STEC were observed at a lower rate in 216 
patients with AP (23.8%) than among patients with D (47.9%) or HUS (85.7%), and 217 
hospitalised patients (63.2%) (Table 1). By contrast, STEC carrying stx2b/stx2e were more 218 
frequent among patients with AP (57.2%) than among patients with D (21.9%), and absent 219 
among HUS patients.  220 
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Finally, eae negative STEC were accountable for 76.2% of patients with AP only, and for 221 
52.1% and 14.3% of patients with D and HUS, respectively. Furthermore, eae negative STEC 222 
were recovered from 36.8% of hospitalised patients. 223 
The distribution of STEC serogroups and of stx2 variants and eae genes among patients with 224 
AP, D, HUS, and hospitalized patients is illustrated in Figure 2C and D, respectively.  225 
The proportions of STEC among E. coli isolated from the patients' stool samples varied 226 
according to serotypes and virulence genes. The majority of the STEC O145, STEC O157, 227 
and STEC O91 isolates (66.7%, 55.6%, and 54.5%, respectively) were found in high numbers 228 
in the stool samples, whereas high proportions were less frequent for serogroups O26 (50%) 229 
and O103 (36.4%), and remarkably less (28.1%), for isolates belonging to serogroups other 230 
than the top five, O80 or O91 (Figure 2E). STEC isolates harbouring stx2a/ stx2c/ stx2d were 231 
observed more frequently in higher proportions than those harbouring stx2b/stx2e (50% and 232 
34.3%, respectively). Similarly, eae positive STEC were found more frequently in high 233 
proportions among E. coli from patients' stool samples than eae negative STEC (44.4% and 234 
33.3%, respectively, Figure 2F). 235 
Among patients with AP, the proportion of STEC in stool was high for 33.3% and low for 236 
47.6%. Among patients with D and HUS, proportions were high for 37% and 42.9%, 237 
respectively, and low for 32.9% and 28.6% (Table 1).  238 
 239 
4. Discussion 240 
 241 
Since 2015, the Swiss FOPH has registered an increase of notifications of STEC related 242 
infections compared to previous years, with the increasing use of stx screening tests driving 243 
this trend (Hächler and Stephan, 2015). In order to estimate any changes in serotype 244 
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distribution and toxin profiles of STEC, this study aimed to identify the serotypes and 245 
virulence genes of 120 STEC isolated from human clinical specimens during 2017.  246 
The five most common serogroups were O157, O103, O26, O91 and O80, with E. coli 247 
O157:H7 accounting for 7.5% of the STEC strains. By comparison, during 2000–2009, 248 
30.6% of the STEC strains isolated from humans in Switzerland were E. coli O157:H7, and 249 
during 2010–2014 this rate further decreased to 19% (Käppeli et al., 2011; Fierz et al., 2017). 250 
Thus, as reported for other countries in the EU, the proportion of STEC O157 isolated from 251 
humans continues to decrease in Switzerland (EFSA, 2017). Similarly, the proportion STEC 252 
O145 which belongs to the top five serogroups in Europe (EFSA, 2017), decreased from 253 
12.6% during 2010–2014 to 5.4% in 2017 (Fierz et al., 2017). By contrast, with regard to the 254 
serogroups that do not belong to the top five, we observed an increase of STEC O80 from 255 
6.3% to 9.2% and of STEC O91 from 3.2% to 9.2%, compared to 2010–2014 (Fierz et al., 256 
2017). In particular, the increase of STEC O80:H2 is noteworthy. This hypervirulent, 257 
multidrug resistant serotype harbours genetic characteristics of a hybrid STEC/ extraintestinal 258 
pathogenic E. coli (ExPEC) pathotype and has recently emerged in France and Switzerland 259 
associated with severe disease including bacteremia and HUS (Soysal et al., 2016; Fierz et 260 
al., 2017; Nüesch-Inderbinen et al., 2018). 261 
Compared to the study period 2010-2014, we also observed a remarkable decrease in the 262 
percentage of STEC harbouring stx2 variants that are associated with severe disease (i.e., 263 
stx2a, stx2c, stx2d) from 50.5% to 33.3%, and of eae positive STEC from 70.5% to 45%. 264 
Simultaneously, we noted a sharp increase from 12.6% to 29.2%, of STEC associated with 265 
stx2b and stx2e, variants that are linked to mild clinical symptoms and asymptomatic carriage 266 
(Stephan and Hoelzle, 2000; Fuller et al., 2011), and to eae negative STEC from 29.5% to 267 
55%. Correlating to this development, the patients' age median increased from 24 years to 268 
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46.5 years, and the proportion of patients ≤ 5 years dropped from 43.2% in 2010–2014 to 269 
10.7% in 2017. 270 
The present study analysed STEC cultured stool samples that were positive for stx by PCR 271 
screening. The relatively low success rate of 27% for isolation of STEC by culture compared 272 
with other studies 72%-96.5% (Friedrich et al., 2002; Tunsjø et al., 2015) may be explained 273 
by the loss of stx genes over time due to transport conditions or time delay to culture in the 274 
reference laboratory. A further explanation is that the concentration of STEC in some of the 275 
stool samples may have been too low to allow detection of isolates. Alternatively, the low 276 
recovery may have been caused by the use of PCR to directly target stx genes in faeces. Free 277 
stx-carrying bacteriophages have been detected at a prevalence of 62% in fecal samples of 278 
healthy people and may thus be responsible for some of the stx positive stool samples 279 
(Martinez-Castillo et al., 2013; Urdahl et al., 2013). Therefore, caution should be employed 280 
when diagnosing disease on the basis of stx positive results obtained directly from faecal 281 
samples.   282 
A definite attribution of the STEC isolates from this study to disease was precluded by the 283 
lack of sufficient information on co-detection of pathogens other than STEC by multiplex 284 
PCR based CIDT. Overall, it cannot be excluded that a certain number of the isolated STEC 285 
were not the actual etiological agent of disease. Indeed, ten (8.3%) of the STEC strains 286 
identified in this study belong to serotypes detected previously in faecal samples of healthy 287 
humans including O8:H25, O128:H10, O146:H21, O146:H28, and O174:H8 (Stephan and 288 
Untermann, 1999; Stephan and Schumacher, 2001; Urdahl et al., 2013).  289 
Our data are supportive of previous studies that established an association of eae negative 290 
STEC with severe clinical symptoms including HUS (Beutin et al., 2004). However, further 291 
studies are needed in order to correlate the presence of infrequently detected STEC serotypes 292 
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and stx2b/stx2e harbouring STEC with the severity of disease and, ultimately, to distinguish 293 
public health relevant infections from the non-relevant. 294 
Conclusively, in spite of the increased notification of STEC during 2017, there was no 295 
evidence for an outbreak situation. Our data are suggestive of an ongoing trend towards a 296 
wider spectrum of serologically different STEC types most likely due to the introduction of 297 
PCR based, increasingly sensitive stx screening tests in laboratory testing practices. This 298 
study emphasises the importance of combining molecular methods of detection with classical 299 
culture techniques to enable the detection of emerging STEC serotypes or outbreak situations. 300 
Moreover, recognition of the trends in serotypes and toxin profiles of STEC is of great 301 
importance in order to estimate epidemiological changes.  302 
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Figure legends 414 
Figure 1: Comparative distribution of serogroups and genotypes of STEC isolated during 415 
2010-2014 and in 2017 from humans.  416 
A: Percentage of the “top five” STEC serogroups and other selected STEC serogroups 417 
isolated during 2010-2014 and in 2017.  418 
B: Percentage of STEC harbouring stx1 and stx2 subtypes, and percentage of eae positive and 419 
eae negative STEC isolated during 2010-2014 and in 2017. 420 
Figure 2: Relationship between STEC type, patients’ age, clinical symptoms, and proportions 421 
of STEC types among E. coli in stool samples.  422 
A: Percentage of patients by age group infected with isolates belonging to the top five STEC 423 
serogroups (O26, O103, O111, O145, or O157), STEC O80, STEC O91, or other STEC 424 
serogroups.  425 
B: Percentage of patients by age group infected with STEC harbouring stx2 virulence genes 426 
associated with high pathogenicity (stx2a/stx2c/stx2d), stx2 genes associated with milder 427 
symptoms (stx2b/stx2e), eae positive (eae +) STEC, and eae negative (eae -) STEC.  428 
C: Distribution of STEC serogroups isolated among patients with abdominal pain only (AP), 429 
diarrhea (D) or the hemorrhagic uremic syndrome (HUS), and from hospitalised patients (H). 430 
D: Distribution of STEC harbouring stx2 virulence genes, and percent eae + and eae - STEC 431 
among patients with AP, D or HUS and among hospitalised patients.  432 
E: Percentage of selected STEC serogroups present in high or low proportions among E. coli 433 
isolated from human stool samples. Stool samples with five or six stx positive colonies out of 434 
six E. coli colonies were classified as high. Samples with one or two STEC per six E. coli 435 
colonies were defined as low proportion.  436 
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F: Percentage of STEC harbouring stx2 subtypes, and percentage of eae positive and eae 437 
negative STEC present in high or low proportions among E. coli isolated from human stool 438 
samples. 439 
 440 
 441 
 442 
 443 
